28 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Gainers

  • Mirati Therapeutics, Inc. MRTX shares increased by 15.4% to $94.00 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.5 billion. According to the most recent rating by Guggenheim, on September 24, the current rating is at Buy.
  • Aileron Therapeutics, Inc. ALRN stock increased by 13.4% to $0.53. The market cap seems to be at $22.6 million.
  • Moleculin Biotech, Inc. MBRX stock moved upwards by 8.1% to $1.20. The market cap seems to be at $50.1 million. The most recent rating by Oppenheimer, on October 17, is at Outperform, with a price target of $2.00.
  • Valeritas Holdings, Inc. VLRX stock surged 7.9% to $1.51. The market cap stands at $10.2 million.
  • Ekso Bionics Holdings, Inc. EKSO stock surged 6.1% to $0.75. The market value of their outstanding shares is at $37.8 million. The most recent rating by H.C. Wainwright, on October 28, is at Buy, with a price target of $1.20.
  • Xenetic Biosciences, Inc. XBIO stock moved upwards by 4.8% to $1.30. The market cap seems to be at $6.5 million.
  • Fresenius Medical Care, Inc. FMS stock surged 4.6% to $34.66. According to the most recent rating by Redburn, on October 23, the current rating is at Neutral.
  • Agile Therapeutics, Inc. AGRX stock surged 4.1% to $0.47. The market cap stands at $65.2 million.
  • Pfizer, Inc. PFE stock increased by 3.6% to $38.60. The market value of their outstanding shares is at $198.7 billion. The most recent rating by Bank of America, on October 17, is at Neutral, with a price target of $37.00.
  • Merck & Co, Inc. MRK stock rose 2.7% to $84.40. The market cap seems to be at $215.5 billion. The most recent rating by Bank of America, on October 17, is at Neutral, with a price target of $90.00.
  • Sunesis Pharmaceuticals, Inc. SNSS shares increased by 2.7% to $0.72. The market value of their outstanding shares is at $90.1 million.
  • Incyte, Inc. INCY shares increased by 2.7% to $82.00. The market value of their outstanding shares is at $16.5 billion. The most recent rating by Mizuho, on October 03, is at Buy, with a price target of $95.00.
  • Grifols, Inc. GRFS shares moved upwards by 2.6% to $21.70. According to the most recent rating by Santander, on October 28, the current rating is at Buy.
  • Guardion Health Sciences, Inc. GHSI shares surged 1.9% to $0.29. The market value of their outstanding shares is at $28.3 million.
  • Melinta Therapeutics, Inc. MLNT shares surged 1.4% to $3.00. The market cap seems to be at $48.6 million. According to the most recent rating by H.C. Wainwright, on August 12, the current rating is at Neutral.
  • Aphria, Inc. APHA stock surged 1.3% to $5.34. The market cap seems to be at $1.7 billion.

 

Losers

  • Orthofix Medical, Inc. OFIX shares decreased by 14.3% to $42.00 during Tuesday's pre-market session. The market cap stands at $1.0 billion. The most recent rating by Cantor Fitzgerald, on October 29, is at Neutral, with a price target of $48.00.
  • HEXO, Inc. HEXO stock fell 10.1% to $2.09. The market cap seems to be at $1.2 billion. According to the most recent rating by Seaport Global, on October 14, the current rating is at Neutral.
  • IVERIC bio, Inc. ISEE shares decreased by 9.4% to $1.54. The market cap seems to be at $46.5 million.
  • Onconova Therapeutics, Inc. ONTX stock decreased by 9.1% to $0.62. The market value of their outstanding shares is at $6.9 million.
  • Avinger, Inc. AVGR stock plummeted 7.5% to $1.36. The market value of their outstanding shares is at $8.4 million.
  • MorphoSys, Inc. MOR stock plummeted 3.8% to $25.88.
  • Gemphire Therapeutics, Inc. GEMP stock declined 3.0% to $0.35. The market cap stands at $5.6 million.
  • Advaxis, Inc. ADXS stock declined 2.9% to $0.29. The market cap stands at $6.1 million.
  • Motif Bio, Inc. MTFB stock decreased by 2.6% to $0.18.
  • Titan Pharmaceuticals, Inc. TTNP shares plummeted 1.9% to $0.17. The market cap seems to be at $4.2 million. The most recent rating by Maxim Group, on October 23, is at Buy, with a price target of $1.00.
  • OrganiGram Holdings, Inc. OGI shares declined 1.1% to $3.60. The market cap seems to be at $710.5 million.
  • Canopy Growth, Inc. CGC shares plummeted 1.0% to $21.44. The market cap seems to be at $11.0 billion. The most recent rating by Piper Jaffray, on October 22, is at Overweight, with a price target of $36.00.

Posted In: BiotechnologyHealth CareHealthcare Stocks Pre-Market MoversTop GainersNewsMovers & ShakersPre-Market OutlookMarketsMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.